11.40
Schlusskurs vom Vortag:
$11.00
Offen:
$11.11
24-Stunden-Volumen:
37,117
Relative Volume:
0.45
Marktkapitalisierung:
$163.35M
Einnahmen:
$166.88M
Nettoeinkommen (Verlust:
$-74.18M
KGV:
-2.2485
EPS:
-5.07
Netto-Cashflow:
$1.14M
1W Leistung:
+1.58%
1M Leistung:
+4.09%
6M Leistung:
-30.57%
1J Leistung:
-59.45%
Anika Therapeutics Inc Stock (ANIK) Company Profile
Firmenname
Anika Therapeutics Inc
Sektor
Telefon
(781) 457-9000
Adresse
32 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie ANIK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ANIK
Anika Therapeutics Inc
|
11.39 | 157.76M | 166.88M | -74.18M | 1.14M | -5.07 |
![]()
ZTS
Zoetis Inc
|
152.78 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.745 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.50 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
305.38 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-17 | Eingeleitet | B. Riley Securities | Buy |
2024-11-01 | Bestätigt | Barrington Research | Outperform |
2023-08-14 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2023-03-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2022-11-09 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2022-10-14 | Fortgesetzt | Stephens | Equal-Weight |
2022-03-09 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2022-03-09 | Herabstufung | Stephens | Overweight → Equal-Weight |
2021-11-16 | Eingeleitet | Stephens | Overweight |
2021-07-16 | Eingeleitet | UBS | Neutral |
2020-12-16 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2020-05-08 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2020-01-21 | Hochstufung | Sidoti | Neutral → Buy |
2020-01-10 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
2019-11-05 | Eingeleitet | BWS Financial | Sell |
2019-09-24 | Bestätigt | Barrington Research | Outperform |
2019-09-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
2019-07-25 | Hochstufung | First Analysis Sec | Neutral → Strong Buy |
2019-02-22 | Herabstufung | First Analysis Sec | Outperform → Neutral |
2019-02-22 | Herabstufung | Sidoti | Buy → Neutral |
2018-07-27 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2018-06-20 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2018-06-20 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
2018-05-04 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
2018-02-23 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
2018-01-24 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
2017-10-27 | Bestätigt | Barrington Research | Outperform |
2016-05-09 | Hochstufung | Singular Research | BUY - Long-Term → Buy |
2016-04-27 | Herabstufung | Northland Capital | Outperform → Market Perform |
2016-02-26 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten
What drives Anika Therapeutics Inc. stock priceSkyrocketing returns - Autocar Professional
Is Anika Therapeutics Inc. a good long term investmentExponential return rates - Autocar Professional
What analysts say about Anika Therapeutics Inc. stockRapid wealth multiplication - jammulinksnews.com
Anika Therapeutics Inc. Stock Analysis and ForecastTriple returns potential - jammulinksnews.com
Why Anika Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
Will Anika Therapeutics Inc. stock benefit from AI tech trendsROI Driven Alerts - Newser
Why Anika Therapeutics Inc. stock is on top investor watchlistsLow Risk Profit Ideas - Newser
Published on: 2025-07-17 22:25:16 - Newser
how anika therapeutics inc. stock performs during market volatilityLow Risk Scalping Alerts - Newser
Anika Therapeutics: Orthopedic Growth and Pipeline Progress Amid Headwinds - AInvest
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025 - GlobeNewswire
Orthopedics Leader Anika Announces Q2 2025 Earnings Call: Key Financial Results Coming July 30 - Stock Titan
How Anika Therapeutics Inc. stock performs during market volatilityFree Stock Portfolio Optimization - Newser
What makes Anika Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
Anika Therapeutics Inc. (NASDAQ:ANIK) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Breakthrough Growth Ahead: Adhesion Barrier Market Set to Surge - openPR.com
Europe Viscosupplementation Market Growth in Future Scope - openPR.com
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
(ANIK) Technical Data - news.stocktradersdaily.com
Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell Microcap Growth Index - MarketScreener
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 2000 Growth-Defensive Index - MarketScreener
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell Small Cap Comp Growth Index - MarketScreener
ANIK SEC FilingsAnika Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Anika Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Anika Therapeutics stockholders approve incentive plan amendment and elect directors - Investing.com
Comparing Vivos (OTCMKTS:RDGL) & Anika Therapeutics (NASDAQ:ANIK) - Defense World
Two Sigma Investments LP Cuts Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Bank of America Corp DE Boosts Stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Finanzdaten der Anika Therapeutics Inc-Aktie (ANIK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anika Therapeutics Inc-Aktie (ANIK) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
Nunes Anne | SVP, Chief Operations Officer |
Oct 01 '24 |
Option Exercise |
0.00 |
2,491 |
0 |
14,211 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):